Lipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Tuesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective on the stock.

Lipocine Price Performance

NASDAQ LPCN opened at $4.72 on Tuesday. The stock’s 50-day moving average is $5.13 and its two-hundred day moving average is $5.40. Lipocine has a fifty-two week low of $2.44 and a fifty-two week high of $11.79. The firm has a market cap of $25.24 million, a P/E ratio of -6.21 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. On average, equities analysts expect that Lipocine will post -0.78 EPS for the current year.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new position in shares of Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.